Evidence map›Paper›PMID 42757486›Full record

ArticleOncology reports2026

Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy.

Hee Jin, Kyung-Hwa Jeon, Chaerin Kang, Joohyun Lee, Yeonjin Lee, Youngjoo Kwon, Yun-Sil Lee

Abstract read
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hee Jin *Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Kyung-Hwa Jeon *Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Chaerin KangGraduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Joohyun LeeGraduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Yeonjin LeeInnovative BioPharmChem Convergence Education and Research Program, Ewha Womans University, Seoul 03760, Republic of Korea.
Youngjoo KwonGraduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Yun-Sil LeeGraduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRCA1 is a multifunctional tumor suppressor that orchestrates homologous recombination repair, chromatin remodeling, cell cycle control and apoptosis. Although pathogenic BRCA1 mutations are relatively uncommon, decreased BRCA1 protein expression, which is typically driven by accelerated proteasomal degradation, is implicated in aggressive breast cancer (BC), particularly triple‑negative (TN)BC. These mutations may modulate therapeutic response to DNA‑damaging agents. Given the absence of clinically available strategies to restore BRCA1 stability, the present study evaluated whether pemetrexed (Peme), a multitargeted antifolate identified through an

Indexed as

BRCA1 ProteinPemetrexedRadiation-Sensitizing AgentsRadiation ToleranceTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceProtein StabilityUbiquitinationXenograft Model Antitumor AssaysBRCA1 ProteinBRCA1 protein, humanPemetrexedRadiation-Sensitizing AgentsBRCA1pemetrexedprotein stabilityradiosensitizationtriple‑negative breast cancer

Identifiers

PMID42757486
PMCPMC13613309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.